Pfizer Secures Metsera Acquisition for $10B Amid Heated Bidding War with Novo Nordisk

Pfizer has acquired Metsera for $10 billion, ending a bidding war with Novo Nordisk. The deal includes a cash payment of $65.60 per share and a contingent value right of up to $20.65 per share. The final offer represents a 160% premium to Metsera's closing price before Pfizer's first offer. The acquisition is expected to close shortly after Metsera's shareholders' meeting on Nov. 13.